Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies

Bone Marrow Transplantation volume 46, pages 238–243 (2011)Cite this article

Subjects

Abstract

Fcγ receptor type IIIA (FCGR3A) has a functional single-nucleotide polymorphism (rs396991), at which a G-to T-point mutation results in an amino acid substitution at position 158 (valine to phenylalanine; V158F). This study examined the effect of the FCGR3A polymorphism in donors and recipients on the clinical outcomes in unrelated HLA fully matched myeloablative BMT. The FCGR3A-V158F genotype was retrospectively analyzed in a total of 99 recipients with myeloid malignancies, and their unrelated donors. The presence of the 158V genotype in recipients showed a statistically better OS (adjusted hazard ratio (HR) 0.49; 95% confidence interval (CI) 0.26–0.93; P=0.03) and TRM (HR 0.30; 95% CI 0.14–0.67; P=0.003) without significant influence on the relapse rate. The recipient 158V genotype was also associated with a significantly reduced risk of chronic GVHD (HR 0.45; 95% CI 0.20–0.99; P=0.049) and a trend toward a reduced risk of grade II–IV acute GVHD (HR 0.55; 95% CI 0.27–1.10; P=0.09), leading to a significantly reduced GVHD-related mortality (HR 0.22; 95% CI 0.06–0.77; P=0.02). The donor FCGR3A polymorphism did not have any effect on the transplant outcomes. These results suggest an association between the recipient FCGR3A genotype and the clinical outcomes after BMT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757–769.

    Article  CAS  PubMed  Google Scholar 

  2. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E . Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 2004; 127: 479–490.

    Article  CAS  PubMed  Google Scholar 

  3. Elmaagacli AH, Koldehoff M, Landt O, Beelen DW . Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 2008; 41: 821–826.

    Article  CAS  PubMed  Google Scholar 

  4. Gerbitz A, Hillemanns P, Schmid C, Wilke A, Jayaraman R, Kolb HJ et al. Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1180–1189.

    Article  CAS  PubMed  Google Scholar 

  5. Kim DH, Jung HD, Lee NY, Sohn SK . Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation 2007; 84: 917–925.

    Article  CAS  PubMed  Google Scholar 

  6. Noori-Daloii MR, Rashidi-Nezhad A, Izadi P, Hossein-Nezhad A, Sobhani M, Derakhshandeh-Peykar P et al. Transforming growth factor-beta1 codon 10 polymorphism is associated with acute GVHD after allogenic BMT in Iranian population. Ann Transplant 2007; 12: 5–10.

    PubMed  Google Scholar 

  7. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 2007; 66: 703–710.

    Article  CAS  PubMed  Google Scholar 

  8. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y et al. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol 2008; 87: 451–458.

    Article  CAS  PubMed  Google Scholar 

  9. Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica 2009; 94: 1427–1434.

    Article  CAS  PubMed  Google Scholar 

  10. Nimmerjahn F, Ravetch JV . Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19–28.

    Article  CAS  PubMed  Google Scholar 

  11. Nimmerjahn F, Ravetch JV . Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34–47.

    Article  CAS  Google Scholar 

  12. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS . The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919–4927:blood-2008-10-161638.

    Article  PubMed  Google Scholar 

  13. Cauza K, Grassauer A, Hinterhuber G, Horvat R, Rappersberger K, Wolff K et al. FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma. J Invest Dermatol 2002; 119: 1074–1079.

    Article  CAS  PubMed  Google Scholar 

  14. Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000; 242: 127–132.

    Article  CAS  PubMed  Google Scholar 

  15. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M . Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood 1997; 90: 1109–1114.

    CAS  PubMed  Google Scholar 

  16. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059–1070.

    Article  CAS  PubMed  Google Scholar 

  17. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D . Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52: 2693–2696.

    Article  CAS  PubMed  Google Scholar 

  18. Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001; 113: 596–599.

    Article  CAS  PubMed  Google Scholar 

  19. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754–758.

    Article  CAS  PubMed  Google Scholar 

  20. Weng WK, Levy R . Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947.

    Article  CAS  Google Scholar 

  21. Sugita N, Yamamoto K, Kobayashi T, Van Der Pol W, Horigome T, Yoshie H et al. Relevance of Fc gamma RIIIa-158V-F polymorphism to recurrence of adult periodontitis in Japanese patients. Clin Exp Immunol 1999; 117: 350–354.

    Article  CAS  PubMed  Google Scholar 

  22. Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD et al. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43: 2793–2800.

    Article  CAS  PubMed  Google Scholar 

  23. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712–3718.

    Article  CAS  Google Scholar 

  24. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110: 2235–2241.

    Article  CAS  PubMed  Google Scholar 

  25. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177–1185.

    Article  CAS  PubMed  Google Scholar 

  26. Livak KJ . Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143–149.

    Article  CAS  PubMed  Google Scholar 

  27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  28. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  29. Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381–387.

    Article  CAS  PubMed  Google Scholar 

  30. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  31. van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, Leppers-van de Straat FG, Kobayashi T et al. Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics 2003; 55: 240–246.

    Article  CAS  PubMed  Google Scholar 

  32. Schultz KR, Paquet J, Bader S, HayGlass KT . Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995; 16: 289–295.

    CAS  PubMed  Google Scholar 

  33. Kamble R, Oholendt M, Carrum G . Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 1201–1202.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107: 2993–3001.

    Article  CAS  PubMed  Google Scholar 

  35. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.

    Article  CAS  PubMed  Google Scholar 

  36. Rowe V, Banovic T, MacDonald KP, Kuns R, Don AL, Morris ES et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006; 108: 2485–2492.

    Article  CAS  PubMed  Google Scholar 

  37. Storek J, Wells D, Dawson MA, Storer B, Maloney DG . Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 489–491.

    Article  CAS  PubMed  Google Scholar 

  38. Michonneau D, Peffault de Latour R, Porcher R, Robin M, Benbunan M, Rocha V et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol 2009; 145: 107–114.

    Article  CAS  Google Scholar 

  39. Lehrnbecher TL, Foster CB, Zhu S, Venzon D, Steinberg SM, Wyvill K et al. Variant genotypes of Fcgamma RIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 2000; 95: 2386–2390.

    CAS  PubMed  Google Scholar 

  40. Ferrara JL, Cooke KR, Teshima T . The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181–187.

    Article  CAS  Google Scholar 

  41. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575–581.

    Article  CAS  PubMed  Google Scholar 

  42. Cauza K, Grassauer A, Hinterhuber G, Horvat R, Rappersberger K, Wolff K et al. Fc[gamma]RIII expression on cultured human keratinocytes and upregulation by interferon-[gamma]. J Invest Dermatol 2002; 119: 1074–1079.

    Article  CAS  PubMed  Google Scholar 

  43. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M . Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26: 5489–5491.

    Article  PubMed  Google Scholar 

  44. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908–3918.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to Drs Hiroko Oshima, Masanobu Oshima and Atsushi Hirao, Ms Kayoko Yamada, Mayu Yamada and Yuki Motohashi at Kanazawa University, and Dr Keitaro Matsuo at Aichi Cancer Center Research Institute for their technical assistance. We thank all the Japan Marrow Donor Program (JMDP) transplant teams who have contributed patients and donors to this study. This study was supported by grants from the Ministry of Health, Labor and Welfare, and the Ministry of Education, Culture, Sports and Technology, and Funds from the Mitani Research and Development Assistance Organization (Kanazawa, Japan) and by the Japan Leukemia Research Fund (Tokyo, Japan).

Author information

Author notes

  1. A Takami and J L Espinoza: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology and Oncology, Kanazawa University Hospital, Kanazawa, Japan

    A Takami, J L Espinoza, K Ishiyama, S Ohtake & S Nakao

  2. Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan

    M Onizuka

  3. Division of Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan

    T Kawase

  4. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Y Kanda

  5. Department of Hematology, Meitetsu Hospital, Nagoya, Japan

    H Sao

  6. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    H Akiyama

  7. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

    K Miyamura

  8. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    S Okamoto

  9. Department of Hematology and Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan

    M Inoue

  10. Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan

    T Fukuda

  11. Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan

    Y Morishima

  12. Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University, Nagoya, Japan

    Y Kodera

Authors
  1. A Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J L Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Onizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Kawase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Sao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Japan Marrow Donor Program

Corresponding author

Correspondence to A Takami.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takami, A., Espinoza, J., Onizuka, M. et al. A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplant 46, 238–243 (2011). https://doi.org/10.1038/bmt.2010.88

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.88

Keywords

This article is cited by

Search

Advanced search

Quick links